natgillin/translations-raw huggingface dataset:
Placebo for 12 weeks (N=113)
RBV-om tijekom 12 tjedana.
Placebo Maintenance
Terapija
Placebo Maintenance (n=110)
Terapija održavanja infliksimabom
Placebo n = 106 to 109*
Placebo n = 106 do 109
Placebo n = 193 wk 12
Placebo n = 193 tj.12
Placebo n = 3,906
Placebo n = 3906
Placebo n=10,049
Placebo n=10 049
Placebo N=106 to 109*
Placebo N=106 do 109
Placebo n=273
Placebo n = 273
Placebo n=382
Place- bo n= 382
Placebo n=427
Place- bo= 427
Placebo N=5,113 n (%)
Placebo N=5113 n (%)
Placebo N=5,125 n(%)
Placebo N=5125 n (%)
Placebo N=8858
Rotarix N=9009 Placebo N=8858
Placebo once weekly and insulin glargine (n=150)
Placebo jedanput na tjedan i inzulin glargin (n=150)
Placebo or Avastin
placebo ili Avastin
Placebo or Bevacizumab
placebo ili bevacizumab
Placebo patients in the 2 Phase III studies in Crohn’s disease, ACCENT I and ACCENT II, received an initial dose of 5 mg/kg infliximab at study start and were on placebo in the maintenance phase.
Bolesnici u placebo skupini u dva klinička ispitivanja faze III u Crohnovoj bolesti, ACCENT I i ACCENT II, primili su inicijalnu dozu infliksimaba od 5 mg/kg na početku ispitivanja, dok su u fazi održavanja primali placebo.
Placebo patients who were considered non-responders were re- randomized 1:1 in a blinded fashion to either apremilast 20 mg twice daily or 30 mg twice daily.
Bolesnici koji su primali placebo i za koje se smatralo da nisu odgovorili na liječenje, bili su ponovno randomizirani u omjeru 1:1 na slijepi način kako bi primali apremilast od 20 mg dvaput na dan ili 30 mg dvaput na dan.
Placebo plus BSC (N=266)
Placebo uz BSC (N=266)
Placebo plus BSC§ (N=253)
Placebo uz najbolju potpornu njegu (N=253)
Placebo plus BSC§ (N=68)
Placebo uz najbolju potpornu njegu (N=68)
Placebo plus docetaxel (N=618)
Placebo plus docetaksel (N=618)
Placebo plus paclitaxel (N=329)
Placebo plus paklitaksel (N=329)
Placebo)
8,40
Placebo)
Placebo
Placebo*** (N = 402)
Gemcitabin/Cisplatin (N = 830)
Placebo*** (N = 402)
placebo*** (N=402)
Placebo*** (N =402)
(N = 222)
Placebo*** (N =402)
Placebo*** (N=402)
Placebo+ C/G (n = 242)
Placebo+ K/G (n=242)
Placebo+ C/G (n=242)
Placebo+ K/G (n=242)
Placebo, (n = 251)
Placebo (n=251)
Placebo- adjusted difference (m)
Placebom prilagođena razlika (m)
Placebo- adjusted difference (m)
Placebom prilagođena razlika(m)
Placebo- adjusted difference (m) 95% CI
Razlika prilagođena za placebo (m) 95% CI
Placebo- controlled clinical trials included approximately 1,800 patients of Hoehn and Yahr stages I – V treated with pramipexole.
Placebom kontrolirana klinička ispitivanja uključila su oko 1800 bolesnika sa stadijem I-V po Hoehn i Yahru liječenih pramipeksolom.
Placebo- controlled clinical trials included approximately 1,800 patients of Hoehn and Yahr stages I – V treated with pramipexole.
Placebom kontrolirana klinička ispitivanja uključila su oko 1800 bolesnika sa stadijem I-V po Hoehn i Yahru, koji su liječeni pramipeksolom.
Placebo- controlled clinical trials included approximately 1800 patients of Hoehn and Yahr stages stages I – IV.
Placebom kontrolirana klinička ispitivanja uključila su oko 1800 bolesnika sa stadijem I – IV po Hoehn i Yahru.
Placebo- controlled clinical trials included approximately 1800 patients of Hoehn and Yahr stages stages I – IV.
Placebom kontrolirana klinička ispitivanja uključila su oko 1800 bolesnika sa stadijem I-IV po Hoehn i Yahru.
Placebo- corrected mean change in HbA1c (%) at week 24 (95%CI)
Placebo korigirana srednja promjena vrijednosti HbA1c (%) u 24. tjednu (95%CI)
Placebo-adjusted difference (m)
Placebom prilagođena razlika (m)
Placebo-adjusted difference (m)
Placebu prilagođena razlika (m)
Placebo-adjusted difference (m) 95% CI, [p-value]
Razlika prilagođena za placebo (m) 95% CI, [p-vrijednost]
Placebo-adjusted difference (ng/L)
Placebom prilagođena razlika (ng/l)
Placebo-controlled clinical trials, over 6 and 12 months, have shown that regular use of salmeterol/fluticasone propionate 50/500 micrograms improves lung function and reduces breathlessness and the use of relief medication.
Placebom kontrolirana klinička ispitivanja tijekom 6 i 12 mjeseci pokazala su da redovita primjena salmeterola/flutikazonpropionata u dozi od 50/500 mikrograma poboljšava funkciju pluća i smanjuje nedostatak zraka i uporabu lijekova za brzo ublažavanje simptoma.
Placebo-Controlled Studies 202/203/204
Placebo-kontrolirana ispitivanja 202/203/204
Placebo-corrected change from baseline in HbA1c (%)† (2-sided 95% CI)
Promjena od početne vrijednosti HbA1c (%)† korigirana za placebo (2-strani 95% CI)
Placebo-corrected change from baseline in HbA1c (%)† (2-sided 95% CI)
Promjena od početne vrijednosti korigirana za placebo HbA1c (%)† (2-strani 95% CI)
Placebo-corrected mean change in HbA1c (%)† (95 % CI)
Srednja vrijednost promjene HbA1c (%)† nakon korekcije u odnosu na placebo (95% CI)
Placebo-corrected treatment effects with PVR were -178 dyne.sec/cm5 (p=0.0051), -195 dyne.sec/cm5 (p=0.0017) and -320 dyne.sec/cm5 (p<0.0001) for sildenafil 20 mg, 40 mg and 80 mg TID,
Učinci liječenja na plućni krvožilni otpor, korigirani za placebo, bili su -178 dyn.s/cm5 (p=0,0051) kod primjene sildenafila u dozi od 20 mg TID, -195 dyn.s/cm5 (p=0,0017) kod primjene sildenafila u dozi od 40 mg TID te -320 dyn.s/cm5 (p < 0,0001) kod primjene sildenafila u dozi od
Placebo-corrected treatment effects with PVR were -178 dyne.sec/cm5 (p=0.0051), -195 dyne.sec/cm5 (p=0.0017) and -320 dyne.sec/cm5 (p<0.0001) for sildenafil 20 mg, 40 mg and 80 mg TID, respectively.
Učinci liječenja na plućni krvožilni otpor, korigirani za placebo, bili su -178 dyn.s/cm5 (p=0,0051) kod primjene sildenafila u dozi od 20 mg TID, -195 dyn.s/cm5 (p=0,0017) kod primjene sildenafila u dozi od 40 mg TID te -320 dyn.s/cm5 (p < 0,0001) kod primjene sildenafila u dozi od
placebo/dex (N=351)
placebo/deks (N=351)
Placebo/MTX- Humira/MTX (95% Confidence Intervalb)
Placebo/MTX - Humira/MTX (95% interval pouzdanostib)
Placebo: 1.87 months
Placebo: 1,87 mjeseci
Placeholder including the weblink of the Package Leaflet on the EMA website
Internetsku poveznicu na Uputu o lijeku na internetskoj stranici Europske agencije za lijekove (EMA).
Placement in sterile field
postavljanje u sterilno polje
Placement or removal of a catheter should be performed at least 12 hours after the administration of low doses of enoxaparin sodium (20 mg once daily, 30 mg once or twice daily or 40 mg once daily) and at least 24 hours after administration of high doses of enoxaparin sodium (0.75 mg/kg bw twice daily, 1 mg/kg bw twice daily or 1.5 mg/kg bw once daily).
Postavljanje ili uklanjanje katetera mora se učiniti najmanje 12 sati nakon primjene niskih doza enoksaparin-natrija (20 mg jedanput na dan, 30 mg jedanput ili dva puta na dan ili 40 mg jedanput na dan) i najmanje 24 sata nakon primjene visokih doza enoksaparinnatrija 0,75 mg/kg TT dva puta na dan, 1 mg/kg TT dva puta na dan ili 1,5 mg/kg TT jedanput na dan).
Placement or removal of a catheter should be performed at least 12 hours after the administration of low doses of enoxaparin sodium (20 mg once daily, 30 mg once or twice daily or 40 mg once daily) and at least 24 hours after administration of high doses of enoxaparin sodium (0.75 mg/kg bw twice daily, 1 mg/kg bw twice daily or 1.5 mg/kg bw once daily).
Postavljanje ili uklanjanje katetera mora se učiniti najmanje 12 sati nakon primjene niskih doza enoksaparinnatrija (20 mg jedanput na dan, 30 mg jedanput ili dva puta na dan ili 40 mg jedanput na dan) i najmanje 24 sata nakon primjene visokih doza enoksaparinnatrija (0,75 mg/kg TT dva puta na dan, 1 mg/kg TT dva puta na dan ili 1,5 mg/kg TT jedanput na dan).
Placental transfer has been seen in pregnant rats, but it is not known whether placental transfer of INTELENCE also occurs in pregnant women.
Prijelaz INTELENCEa kroz placentu opažen je u skotnih ženki štakora, ali nije poznato dolazi li do tog prijelaza i u trudnica.
Placental transfer of trastuzumab during the early (days 20–50 of gestation) and late (days 120–150 of gestation) foetal development period was observed.
Primijećeno je da trastuzumab prolazi kroz posteljicu za vrijeme ranog (20.-50. dan gestacije) i kasnog (120.-150. dan gestacije) perioda fetalnog razvoja.
Placing the administration system on the thigh
Namještanje sustava za primjenu na bedro
Placing used sharps containers in the household waste should be avoided.
Odlaganje spremnika s oštrim predmetima u kućni otpad treba izbjegavati.
Placing used sharps containers in the household waste should be avoided.
Odlaganje spremnika za odladanje oštrih predmeta u kućni otpad treba izbjegavati.
plan to have surgery are due to get an injection of dye or contrast agent as part of an X-ray
planirate operativni zahvat trebate primiti injekciju kontrastnog sredstva kao dio rendgenskog snimanja
plan to have surgery including dental surgery
planirate ići na kirurški zahvat, uključujući i stomatološki,
plan to have surgery. are due to get an injection of dye or contrast agent as part of an X-ray.
e planirate podvrgnuti kirurškom zahvatu. trebate dobiti injekciju boje ili kontrastno sredstvo kao dio rendgenske pretrage.
PLANNING WHEN TO TAKE BONVIVA
PLANIRANJE VREMENA UZIMANJA LIJEKA BONVIVA
Plantar erythema
plantarni eritem
plaque building up inside your arteries which could lead to heart attack and stroke;
tvaranje plakova na stijenkama arterija koje mogu dovesti do srčanog ili moždanog udara;
plaque building up inside your arteries which could lead to heart attack and stroke;
tvaranje plakova na stjenkama arterija koje mogu dovesti do srčanog ili moždanog udara;
Plaque psoriasis
Plak psorijaze
Plaque psoriasis - in adults and children aged 12 years and older
Plak psorijaza – u odraslih i djece u dobi od 12 godina i starijih
Plasma
plazma
Plasma aliskiren exposure in rats aged 14 days was between 85- and 387- fold higher than that in adult rats aged 64 days.
Izloženost aliskirenu u plazmi u štakora u dobi od 14 dana bila je od 85 do 387 puta veća nego u odraslih štakora starih 64 dana.
Plasma anti-IIa activity after subcutaneous administration is approximately ten-fold lower than anti-Xa activity.
Anti-IIa aktivnost u plazmi nakon supkutane primjene je približno deset puta niža nego anti-Xa aktivnost.
Plasma ara-G Cmax values generally occurred at the end of the nelarabine infusion and were generally higher than nelarabine Cmax values, suggesting rapid and extensive conversion of nelarabine to ara-G.
Vrijednosti Cmax ara-G u plazmi u načelu su se bilježile na kraju infuzije nelarabina i bile općenito više od vrijednosti Cmax nelarabina, što upućuje na brzu i opsežnu pretvorbu nelarabina u ara-G.
Plasma clearance decreases markedly at high doses; it falls from approximately 40 l/kg/day at the dose of 600 mg/day to about 8 l/kg/day at the dose of 2,400 mg.
Plazma klirens se značajno smanjuje pri visokim dozama; pada od približno 40 l/kg/dan pri dozi od 600 mg/dan do oko 8 l/kg/dan pri dozi od 2400 mg.
Plasma clearance in patients with renal impairment (creatinine clearance 41-60 ml/min.) decreased to about 67 % compared with control patients.
Klirens plazme u bolesnika s oštećenjem bubrega (klirens kreatinina 41-60 ml/min) smanjio se na približno 67% u usporedbi s kontrolnom skupinom bolesnika.
Plasma clearance in patients with renal impairment (creatinine clearance 41-60 ml/min.) decreased to about 67 % compared with control patients.
Plazmatski klirens u bolesnika s oštećenjem bubrega (klirens kreatinina 41-60 ml/min) smanjio se na približno 67% u usporedbi s kontrolnom skupinom bolesnika.
Plasma clearance of AsIII was not altered in patients with mild renal impairment (creatinine clearance of 50-80 mL/min) or moderate renal impairment (creatinine clearance of 30-49 mL/min).
Plazmatski klirens AsIII nije bio izmijenjen u bolesnika s blagim oštećenjem bubrega (klirens kreatinina od 50 do 80 ml/min) ili umjerenim oštećenjem bubrega (klirens kreatinina od 30 do 49 ml/min).
Plasma clearance of canrenone is
Plazmatski klirens kanrenona je 1.45 
Plasma clearance of total topotecan (active and inactive form) in patients with hepatic impairment only decreased by about 10 % compared with the control group of patients.
Plazmatski klirens ukupnog topotekana (aktivni i inaktivni oblik) kod bolesnika s oštećenjem jetre smanjio se samo oko 10% u usporedbi s kontrolnom skupinom bolesnika.
Plasma clearance of total topotecan (active and inactive form) in patients with hepatic impairment only decreased by about 10 % compared with the control group of patients.
Ukupni klirens plazme za topotekan (aktivni i neaktivni oblik) kod bolesnika s oštećenjem jetre smanjio se samo oko 10% u usporedbi s kontrolnom skupinom.
Plasma clearance, volume of distribution and half- life are independent of dose.
Klirens iz plazme, volumen raspodjele i poluvrijeme ne ovise o dozi.
Plasma Cmax and AUC of dolutegravir following administration of Triumeq with a high fat meal were 37% and 48% higher, respectively, than those following administration of Triumeq in the fasted state).
Plazmatski Cmax odnosno AUC dolutegravira nakon primjene lijeka Triumeq uz obrok s visokim udjelom masnoća bili su 37% odnosno 48% veći nego nakon primjene lijeka Triumeq natašte.
Plasma concentrations following a 1 g and 2 g intravenous dose of ertapenem are slightly higher (approximately 39 % and 22 %, respectively) in healthy elderly adults ( 65 years) relative to young adults ( 65 years).
Koncentracije u plazmi nakon primjene intravenske doze od 1 g i 2 g nešto su više (približno 39%, odnosno 22%) u zdravih starijih osoba ( 65 godina), u odnosu na mlađe odrasle osobe (65 godina).
plasma concentrations may be
koncentracije nevirapina mogle
Plasma concentrations may be increased due to P-glycoprotein inhibition by Kaletra.
Koncentracije u plazmi mogu biti povećane zbog inhibicije P- glikoproteina izazvane lijekom Kaletra.
Plasma concentrations may be increased due to P-glycoprotein inhibition by lopinavir/ritonavir.
Koncentracije u plazni mogu biti povećane zbog inhibicije P- glikoproteina izazvane lopinavirom/ritonavirom.
Plasma concentrations of
Koncentracije blokatora
Plasma concentrations of 9-cis-retinoic acid were evaluated during clinical studies in patients with cutaneous lesions of AIDS-related KS after repeated multiple-daily dose application of Panretin gel for up to 60 weeks.
Koncentracije 9-cis-retinoične kiseline u plazmi bile su procijenjene tijekom kliničkih ispitivanja u bolesnika s kožnim lezijama KS povezanog s AIDS-om nakon ponovne višestruke primjene dnevne doze Panretin gela u trajanju do 60 tjedana.
Plasma concentrations of atorvastatin, pitavastatin, fluvastatin, pravastatin or rosuvastatin are expected to increase when co-administered with atazanavir/cobicistat or darunavir/cobicistat.
Očekuje se da će se koncentracije atorvastatina, pitavastatina, fluvastatina, pravastatina ili rosuvastatina u plazmi povećati s istovremenom primjenom atazanavira/kobicistata ili darunavira/kobicistata.
Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared to subjects with normal renal function.
Koncentracije metabolita bosentana u plazmi povećale su se otprilike dvostruko u tih bolesnika u odnosu na bolesnike s normalnom bubrežnom funkcijom.
Plasma concentrations of both pro-drug and active metabolite are proportional to dose and are unaffected by co-administration with food.
Koncentracije predlijeka i aktivnog istodobno uzimanje hrane.
Plasma concentrations of both pro-drug and active metabolite are proportional to dose and are unaffected by co-administration with food.
Koncentracije predlijeka i aktivnog metabolit istodobno uzimanje hrane.
Plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 11 hours in healthy elderly subjects.
Koncentracije dabigatrana u plazmi pokazale su bieksponencijalni pad, s prosječnim terminalnim poluvijekom od 11 sati u zdravih starijih osoba.
Plasma concentrations of DM1 and DM1-containing catabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients with and without hepatic impairment.
Plazmatske koncentracije DM1 i katabolita koji sadrže DM1(Lys-MCC-DM1 i MCC-DM1) bile su niske i usporedive u bolesnika s oštećenjem i onih bez oštećenja jetrene funkcije.
Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal half-life for linagliptin more than 100 hours), that is mostly related to the saturable, tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of the drug.
Koncentracije linagliptina u plazmi padaju na trofazni način s dugim terminalnim poluvijekom (terminalni poluvijek linagliptina iznosi više od 100 sati), što je uglavnom povezano sa saturabilnim, čvrstim vezanjem linagliptina na DPP-4 te ne pridonosi akumulaciji lijeka.
plasma concentrations of midazolam are
koncentracije midazolama u plazmi biti
Plasma concentrations of OATP
Koncentracije supstrata
Plasma concentrations of pitavastatin may be increased if co-administered with EVOTAZ.
Istodobna primjena s lijekom EVOTAZ može povisiti plazmatske koncentracije pitavastatina.
Plasma concentrations of telaprevir can be reduced by concomitant use of the herbal preparation St John’s wort (Hypericum perforatum).
Istodobna primjena biljnih pripravaka gospine trave (Hypericum perforatum) može smanjiti koncentracije telaprevira u plazmi.
Plasma concentrations of telmisartan are generally 2 – 3 times higher in females than in males.
Koncentracije telmisartana u plazmi su općenito 2-3 puta veće kod žena nego kod muškaraca.
Plasma concentrations of total topotecan (i.e. lactone and carboxylate forms) and topotecan lactone (active moiety) peak at approximately 2.0 hours and 1.5 hours, respectively, and decline bi-exponentially with mean terminal half-life of approximately 3.0 to 6.0 hour.
Vršne koncentracije ukupnog topotekana u plazmi (tj. laktonski i karboksilni oblici) postižu se približno nakon 2,0 sata, a topotekan laktona (aktivna tvar) nakon 1,5 sat i opadaju bieksponencijalno sa srednjim poluvijekom od približno 3,0 do 6,0 sati.
Plasma concentrations of trazodone may be increased when co-administered with cobicistat.
Koncentracije kolhicina u plazmi mogu se povećati kod istovremene primjene s kobicistatom.
Plasma concentrations of trazodone may be increased when co-administered with cobicistat.
Koncentracije trazodona u plazmi mogu se povećati kod istovremene primjene s kobicistatom.
Plasma concentrations of trazodone may be increased when co-administered with EVOTAZ.
Istodobna primjena s lijekom EVOTAZ može povisiti plazmatske koncentracije trazodona.
Plasma concentrations that are well tolerated in animals exceed at least 62-fold (Cmax) and 104-fold (Cavg) the plasma concentrations in paediatric SJIA patients, treated with up to 4 mg/kg via the subcutaneous route every 4 weeks.
Koncentracije u plazmi koje su se dobro podnosile u životinja premašuju najmanje 62 puta (Cmax) i 104 puta (Cavg) koncentracije u plazmi u pedijatrijskih bolesnika sa SJIA-om, liječenih sa do 4 mg/kg potkožno svaka 4 tjedna.
Plasma concentrations were obtained from a subgroup of patients in the two DME pivotal studies prior to dosing and on days 1, 7, and 21, and months 1.5 and 3 following intravitreal injection of a single intravitreal implant containing 350 µg or 700 µg dexamethasone.
Koncentracija u plazmi mjerena je u uzorcima podskupine bolesnika dva pivotalna ispitivanja DME, i to prije primjene doze te 1., 7. i 21. dan i 1,5 i 3 mjeseca nakon intravitrealne injekcije jednog intravitrealnog implantata koji sadrži 350 µg odnosno 700 µg deksametazona.
plasma concentrations which may
koncentracije nevirapina, što bi
Plasma concentrations ↑ Cortisol levels ↓ 86%
Flutikazon propionat:
Plasma concentrations ↑ Cortisol levels ↓ 86%
Plazmatske koncentracije ↑ Razine kortizola ↓ 86
plasma concentrations.
antiaritmika u plazmi.
plasma concentrations.
antineoplastika u plazmi.
plasma concentrations.
antipsihotika u plazmi.
plasma concentrations.
β-blokatora u plazmi.
Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients.
U svih bolesnika treba određivati CPK u plazmi prije početka terapije i u pravilnim vremenskim razmacima tijekom terapije (najmanje jedanput tjedno).
Plasma creatinine levels may rise initially due to inhibition of the renal tubular excretion of creatinine and are not necessarily indicative of a deterioration in renal function. .
Na početku liječenja razine kreatinina u plazmi mogu porasti zbog inhibicije izlučivanja kreatinina bubrežnim tubulima, stoga povišene vrijednosti ne moraju nužno upućivati na pogoršanje bubrežne funkcije.
Plasma creatinine values should be measured prior to and 7 days after initiation of dronedarone.
Treba izmjeriti vrijednosti kreatinina u plazmi prije početka i 7 dana nakon početka liječenja dronedaronom.
Plasma elimination half-life mean values ranged from approximately 5–6 hours for verteporfin.
Srednje vrijednosti poluvremena eliminacije verteporfina iz plazme kreću se u rasponu od 5 do 6 sati.
Plasma eltrombopag Cmax and AUC(0-) estimates for patients with HCV enrolled in the Phase 3 studies are presented for each dose studied in Table 9.
Procjene Cmax i AUC(0-) eltrombopaga u plazmi za bolesnike s HCV-om uključene u fazu III ispitivanja za svaku ispitivanu dozu prikazane su u tablici 9.
Plasma eltrombopag concentration-time data collected in 590 subjects with HCV enrolled in Phase III studies TPL103922/ENABLE 1 and TPL108390/ENABLE 2 were combined with data from patients with HCV enrolled in the Phase II study TPL102357 and healthy adult subjects in a population PK analysis.
Podaci o koncentraciji eltrombopaga u plazmi tijekom vremena za 590 ispitanika s HCV-om uključenih u fazu III ispitivanja TPL103922/ENABLE 1 i TPL108390/ENABLE 2 bile su združene s podacima bolesnika s HCV-om uključenih u fazu II ispitivanja TPL102357 i zdravih odraslih ispitanika u populaciji za PK analizu.
Plasma exposure (AUC and Cmax) to valdecoxib was increased (38% and 24%, respectively) when co- administered with ketoconazole (CYP3A4 inhibitor), however, a dosage adjustment should not generally be necessary for patients receiving ketoconazole.
Izloženost valdekoksibu u plazmi (AUC i Cmax) bila je povećana (38% odnosno 24%) kad se istodobno primjenjivao ketokonazol (inhibitor CYP3A4), međutim, prilagodba doziranja općenito ne bi trebala biti neophodna u bolesnika koji primaju ketokonazol.
Plasma exposure (AUC and Cmax) to valdecoxib was increased (62% and 19%, respectively) when co- administered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of parecoxib should be reduced in those patients who are receiving fluconazole therapy.
Izloženost valdekoksibu u plazmi (AUC i Cmax) bila je povećana (62% odnosno 19%) kad se primjenjivao istodobno s flukonazolom (pretežno inhibitorom CYP2C9), što pokazuje da se doza parekoksiba mora sniziti u onih bolesnika koji primaju terapiju flukonazolom.
Plasma exposure (AUCτ,ss) was increased by 26% for a 42 kg patient (2.5th percentile) and decreased by 22% for a 95 kg patient (97.5th percentile) relative to a patient weighing 62 kg (median body weight of patients in the overall patient population).
Izloženost u plazmi (AUCτ,ss) se povećala za 26% kod bolesnika s 42 kg (2,5 percentila), te smanjila za 22% kod bolesnika od 95 kg (97,5 percentila) u odnosu na bolesnike s 62 kg (medijan tjelesne težine bolesnika u ukupnoj bolesničkoj populaciji).
Plasma exposure of simeprevir (AUC) in HCV infected patients was about 2- to 3-fold higher compared to that observed in healthy subjects.
Izloženost simepreviru u plazmi (AUC) u bolesnika inficiranih HCV- om bila je oko 2- do 3-puta viša u usporedbi s onom uočenom kod zdravih ispitanika.
plasma exposures of
AUC 0,68 (0,63-0,72)
Plasma exposures to ivacaftor in mice at the non- carcinogenic dosage (200 mg/kg/day, the highest dosage tested) were approximately 4- to 7-fold higher than the exposure measured in humans following ivacaftor therapy.
Izloženost miševa ivakaftoru u plazmi pri nekancerogenim dozama (200 mg/kg na dan, najviša ispitana doza) bila je približno 4 do 7 puta veća od izloženosti izmjerene u ljudi nakon terapije ivakaftorom.